2025-11-16 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data you provided.  I'll start with the numbers, add some simple analysis, and summarize at the end.

## Teladoc Health Inc. (TDOC) Analysis

**0) Overview**

*   **Ticker:** TDOC
*   **Company:** Teladoc Health Inc.
*   **Description:** Teladoc Health Inc. is a telehealth company that provides virtual healthcare services.

**1) Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -66.14%
*   **VOO Cumulative Return:** 100.11%
*   **Absolute Divergence:** -166.25% (TDOC significantly underperformed VOO)
*   **Relative Divergence:** 0.8 (On a scale where 0 is the worst and 100 is the best relative divergence between min/max range, TDOC is at 0.8)

**Analysis of Alpha/Beta**

| Year       | CAGR     | MDD   | Alpha    | Beta   | Cap(B) |
|------------|----------|-------|----------|--------|--------|
| 2015-2017  | 77.0%    | 70.4% | 51.0%    | -0.0   | 6.3    |
| 2016-2018  | 101.0%   | 69.4% | 86.0%    | -0.0   | 9.0    |
| 2017-2019  | 141.0%   | 73.8% | 118.0%   | 0.4    | 15.2   |
| 2018-2020  | 105.0%   | 80.9% | 81.0%    | 0.3    | 36.3   |
| 2019-2021  | -78.0%   | 80.9% | -125.0%  | 0.3    | 16.6   |
| 2020-2022  | -252.0%  | 85.9% | -251.0%  | -0.9   | 4.3    |
| 2021-2023  | -315.0%  | 85.9% | -316.0%  | -1.8   | 3.9    |
| 2022-2024  | -93.0%   | 85.9% | -113.0%  | -2.0   | 1.6    |
| 2023-2025  | -37.0%   | 81.6% | -100.0%  | -0.8   | 1.2    |

*   **Analysis:**  The table shows a drastic shift in performance over time.  Early periods (2015-2020) had high growth (CAGR), positive Alpha (outperformance), and low Beta (low market sensitivity).  However, more recent periods (2019-2025) show significant negative returns (CAGR), negative Alpha (underperformance), and negative Beta values, indicating an inverse correlation with the market. The MDD remained fairly constant in 70~80%, meaning that risk management would have been challenging. The market cap has been sharply reduced since 2018-2020.

**2) Recent Stock Price Movement**

*   **Current Price:** 6.92
*   **Previous Close:** 7.07
*   **Change:** -2.12%
*   **5-Day Moving Average:** 7.304
*   **20-Day Moving Average:** 8.143
*   **60-Day Moving Average:** 8.1217

*   **Analysis:** The stock price is below all three moving averages, suggesting a short-term and medium-term downward trend.  The recent price drop (-2.12%) indicates continued negative momentum.

**3) Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 19.17 (Oversold)
*   **PPO:** -2.03
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (117 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Divergence Change:** +0.8 (Short-term increase)
*   **Expected Return:** -9790.3% (Long-term expected return vs. S&P 500)

*   **Analysis:** The RSI indicates the stock is oversold, which *could* suggest a potential for a rebound. The negative PPO supports the recent downward trend. Despite the MRI suggesting a medium investment, the *extremely* negative expected return is a major red flag. The recent negative change in price may indicate a high possibility of a short-term sharp decline.

**4) Recent News & Significant Events**

*   **Negative Sentiment:** Multiple articles highlight concerns, including being a "value stock to steer clear of" and trading down with other struggling stocks.
*   **Mixed Coverage:** BMO Capital initiated coverage with a "Market Perform" rating (neutral).
*   **Weak Results:** Teladoc's Q3 loss widened due to a weak BetterHelp unit.
*   **Market Context:** Articles discuss Teladoc's position in the growing telemedicine market, but also mention competitors like Hims & Hers.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (2.65)
*   **Target Price:** Average: 9.26, High: 12.00, Low: 7.00
*   **Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price is higher than the current price, indicating potential upside, but the range is wide, reflecting uncertainty. No recent rating changes are available in your dataset.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-30 | -0.28 | 0.63 B$    |
| 2025-07-30 | -0.19 | 0.63 B$    |
| 2025-05-01 | -0.53 | 0.63 B$    |
| 2024-10-31 | -0.19 | 0.64 B$    |
| 2025-10-30 | -0.19 | 0.64 B$    |

*   **Analysis:**  Teladoc has consistently reported losses per share (EPS). Revenue has been relatively flat.

**6) Financial Information**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $0.63B    | 70.12%        |
| 2025-06-30 | $0.63B    | 69.85%        |
| 2025-03-31 | $0.63B    | 68.73%        |
| 2024-12-31 | $0.64B    | 70.50%        |
| 2024-09-30 | $0.64B    | 71.94%        |

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-09-30 | $1.39B    | -3.56%  |
| 2025-06-30 | $1.42B    | -2.30%  |
| 2025-03-31 | $1.43B    | -6.52%  |
| 2024-12-31 | $1.49B    | -3.25%  |
| 2024-09-30 | $1.51B    | -2.21%  |

*   **Analysis:** Revenue is stable. Profit margins are relatively high. However, the Return on Equity (ROE) is consistently negative, indicating the company is not generating profits from its equity. Equity is also decreasing over time.

**7) Overall Summary**

Teladoc Health Inc. (TDOC) is facing significant challenges.

*   **Poor Performance:**  The stock has drastically underperformed the S&P 500, with a large negative cumulative return.
*   **Downward Trend:** Recent stock price movement indicates a continuing downward trend.
*   **Negative Profitability:** The company is not profitable, with negative EPS and ROE.
*   **Mixed Signals:** While the RSI suggests the stock may be oversold, the extremely negative expected return raises serious concerns. Analyst opinions are neutral, but target prices have a wide range.
*   **Negative News:** Recent news headlines are largely negative.

**Conclusion:**

Based on this data, TDOC appears to be a high-risk investment. The company needs to demonstrate a clear path to profitability and address the concerns raised in recent news articles to regain investor confidence.
